1. Home
  2. AGIO
  3. AGIO News

Latest Agios Pharmaceuticals Inc. (AGIO) News on February 22, 2025

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
AGIO

GlobeNewswire

2 days ago

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank
AGIO

TipRanks

7 days ago

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO

Zacks

8 days ago

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
AGIO

Simply Wall St.

8 days ago

Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...
AGIO

GuruFocus.com

8 days ago

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years
AGIO

Benzinga

9 days ago

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
AGIO

Zacks

9 days ago

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

AGIO

MT Newswires

9 days ago

Agios Pharmaceuticals' Q4 Loss Widens, Revenue Rises

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
AGIO

GlobeNewswire

9 days ago

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
AGIO

GlobeNewswire

9 days ago

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

Agios Pharmaceuticals price target lowered to $54 from $55 at BofA
AGIO

TipRanks

10 days ago

Agios Pharmaceuticals price target lowered to $54 from $55 at BofA

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now
AGIO

Insider Monkey

10 days ago

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now

AGIO

MT Newswires

11 days ago

BofA Securities Trims Price Target on Agios Pharmaceuticals to $54 From $55, Maintains Buy Rating

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
AGIO

GlobeNewswire

16 days ago

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential
AGIO

Insider Monkey

a month ago

Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
AGIO

GlobeNewswire

a month ago

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
AGIO

Zacks

a month ago

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

AGIO

MT Newswires

a month ago

Agios Pharmaceuticals Says FDA Accepted Supplemental New Drug Application for Pyrukynd

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
AGIO

GlobeNewswire

a month ago

FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia

AGIO

MT Newswires

a month ago

BofA Securities Adjusts Price Target on Agios Pharmaceuticals to $55 From $60, Maintains Buy Rating

How to Navigate the Stock and Bond Markets in 2025
AGIO

The Wall Street Journal

2 months ago

How to Navigate the Stock and Bond Markets in 2025

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
AGIO

GlobeNewswire

2 months ago

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

AGIO

MT Newswires

2 months ago

Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
AGIO

GlobeNewswire

2 months ago

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

Here's Why Agios Stock Plummeted More Than 20% on Monday
AGIO

Zacks

2 months ago

Here's Why Agios Stock Plummeted More Than 20% on Monday

Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank
AGIO

TipRanks

2 months ago

Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank

AGIO

MT Newswires

2 months ago

RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating

Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
AGIO

Investor's Business Daily

2 months ago

Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug

AGIO

MT Newswires

2 months ago

Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
AGIO

GlobeNewswire

2 months ago

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
AGIO

Zacks

3 months ago

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?
AGIO

Zacks

3 months ago

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios
AGIO

Zacks

3 months ago

Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios

4 Medical Product Stocks to Buy From a Prospective Industry
AGIO

Zacks

3 months ago

4 Medical Product Stocks to Buy From a Prospective Industry

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
AGIO

Zacks

3 months ago

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News
AGIO

Simply Wall St.

3 months ago

Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
AGIO

GlobeNewswire

4 months ago

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
AGIO

Zacks

4 months ago

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
AGIO

Zacks

4 months ago

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
AGIO

Simply Wall St.

4 months ago

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
AGIO

GuruFocus.com

4 months ago

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

AGIO

MT Newswires

4 months ago

Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
AGIO

Zacks

4 months ago

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates

AGIO

Associated Press Finance

4 months ago

Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Reports Business Highlights and Third Quarter 2024 Financial Results
AGIO

GlobeNewswire

4 months ago

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
AGIO

GlobeNewswire

4 months ago

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
AGIO

GlobeNewswire

4 months ago

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

AGIO

MT Newswires

4 months ago

Scotiabank Initiates Agios Pharmaceuticals at Sector Outperform With $51 Price Target

AGIO

MT Newswires

5 months ago

Agios Pharmaceuticals' Shares Fall After Downgrade From Leerink Partners

Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
AGIO

Zacks

5 months ago

Do Options Traders Know Something About Agios (AGIO) Stock We Don't?

AGIO

MT Newswires

5 months ago

Leerink Partners Downgrades Agios Pharmaceuticals to Market Perform From Outperform, Price Target is $56

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
AGIO

Investor's Business Daily

5 months ago

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results
AGIO

Insider Monkey

5 months ago

Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
AGIO

Simply Wall St.

5 months ago

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
AGIO

Zacks

5 months ago

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation
AGIO

Pharmaceutical Technology

5 months ago

Agios Pharmaceuticals’ tebapivat gains FDA orphan drug designation

AGIO

MT Newswires

5 months ago

Agios Pharmaceuticals Says FDA Granted Orphan Drug Designation to Blood Disorder Drug Candidate Tebapivat

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
AGIO

GlobeNewswire

5 months ago

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
AGIO

Zacks

6 months ago

Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
AGIO

GlobeNewswire

6 months ago

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

AGIO

MT Newswires

6 months ago

Agios Pharmaceuticals Insider Sold Shares Worth $474,140, According to a Recent SEC Filing

Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now?
AGIO

Insider Monkey

6 months ago

Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now?

Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?
AGIO

Insider Monkey

6 months ago

Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
AGIO

GlobeNewswire

7 months ago

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results
AGIO

Simply Wall St.

7 months ago

Here's What Analysts Are Forecasting For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) After Its Second-Quarter Results

Agios Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
AGIO

Simply Wall St.

7 months ago

Agios Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
AGIO

Zacks

7 months ago

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12%
AGIO

Simply Wall St.

7 months ago

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12%

AGIO

MT Newswires

7 months ago

RBC Raises Price Target on Agios Pharmaceuticals to $55 From $53, Keeps Outperform Rating

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
AGIO

Benzinga

7 months ago

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

AGIO

MT Newswires

7 months ago

Agios Pharmaceuticals Shares Down After Q2 Results Fall Short of Market Expectations

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
AGIO

Zacks

7 months ago

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates

AGIO

Associated Press Finance

7 months ago

Agios Pharmaceuticals: Q2 Earnings Snapshot

Agios Reports Business Highlights and Second Quarter 2024 Financial Results
AGIO

GlobeNewswire

7 months ago

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused
AGIO

GlobeNewswire

7 months ago

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for
AGIO

Zacks

7 months ago

Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
AGIO

Zacks

7 months ago

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Has Found A Path To Profitability
AGIO

Simply Wall St.

7 months ago

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Has Found A Path To Profitability

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
AGIO

GlobeNewswire

7 months ago

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
AGIO

Zacks

8 months ago

Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?

Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year
AGIO

Simply Wall St.

8 months ago

Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
AGIO

GlobeNewswire

8 months ago

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
AGIO

Zacks

8 months ago

Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?

Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO)
AGIO

GuruFocus.com

8 months ago

Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO)

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
AGIO

GlobeNewswire

9 months ago

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
AGIO

Zacks

9 months ago

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

AGIO

MT Newswires

9 months ago

Goldman Sachs Adjusts Price Target on Agios Pharmaceuticals to $53 From $33, Maintains Neutral Rating

AGIO

MT Newswires

9 months ago

RBC Raises Price Target on Agios Pharmaceuticals to $53 From $44, Maintains Outperform Rating

AGIO

MT Newswires

9 months ago

Agios Says of Trial of Blood Disorder Drug Mitapivat Met Primary Endpoint; Shares Rise

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
AGIO

GlobeNewswire

9 months ago

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
AGIO

GlobeNewswire

9 months ago

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
AGIO

Zacks

9 months ago

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
AGIO

Zacks

9 months ago

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Agios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal
AGIO

Investor's Business Daily

9 months ago

Agios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal

AGIO

Associated Press Finance

9 months ago

Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024

Are Medical Stocks Lagging Lantheus (LNTH) This Year?
AGIO

Zacks

9 months ago

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

AGIO

MT Newswires

9 months ago

Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million

Agios cashes in on cancer drug again with $905M Royalty Pharma deal
AGIO

BioPharma Dive

9 months ago

Agios cashes in on cancer drug again with $905M Royalty Pharma deal

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
AGIO

GlobeNewswire

9 months ago

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%
AGIO

Zacks

9 months ago

How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%

Share on Social Networks: